

Pfizer 2021 Disclosure for Patient Organisations

	Patient Organisation Name	Country	Types of the Support or Services Provided						Optional Indication of Patient Organisation's Total Income and/or the Company's Support as a Percentage	Description of Support		
			Financial Support			Non-financial support	Contracted services (Fees and expenses should be disclosed separately)				Non-monetary Benefit for PO ²	
			Grants add a line for each Grant	Sponsorship of Meetings add a line for each sponsorship	Other Sponsorships add a line for each sponsorship	Donations add a line for each donation	Fees	Out of pocket / expenses				
	ACTION DUCHENNE	UK						£400.00			£494,338 (0.08%)	To engage with two representatives from Action Duchenne to provide consultancy services on living with Duchenne - The Patient Voice at a Pfizer meeting.
	ACTION DUCHENNE	USA	£10,000.00								£494,338 (1.98%)	A grant provided to Action Duchenne to deliver a nationwide roadshow of 24 workshops over 12 months focusing on supporting families by making them aware of the facts behind key questions. Action Duchenne will focus on explaining research information in an easy-to-understand way to empower families to make informed choices about taking part in research and clinical trials, dietary supplements, hydrotherapy and exercise, carrier testing and family planning.
	ARTHRITIS AND MUSCULOSKELETAL ALLIANCE	UK		£5,000.00							£92,510 (5.4%)	To support Arthritis Musculoskeletal Alliance to deliver ARMA Virtual Conference 2021 on 6th December 2021 in return for : - Logo on the event page on the ARMA Website - Acknowledgement of sponsorship in Social Media and ARMA Newsletter - 3 delegate passes - Embedded hyperlink on the event page on the ARMA Website - Virtual Exhibition space at the event including opportunity to host a presentation in the exhibition area publicised to all delegates - A question of choice included within the delegate evaluation
	ASPERGILLOSIS TRUST	UK	£3,642.00								Recently registered charity. Financial information not available	To offer a charitable contribution to support the Aspergillosis Trust by providing funding. The main objective of this support is to aid the Aspergillosis Trust in delivering a programme explaining the most common conditions that come under the term Aspergillosis, with the aim of educating newly diagnosed patients which will support the public interest by educating individuals and families about sound health practices in order to empower them to improve their health. The payment will be made direct to the organisation.
	ASTHMA UK AND BRITISH LUNG FOUNDATION	UK	£2,500.00								£15,105,000 (0.00002%)	To offer a charitable contribution to support Asthma United Kingdom & British Lung Foundation Partnership by providing funding. The main objective of this support is to contribute to the ongoing development, purpose and value of the Asthma UK and British Lung Foundation Partnership's Task Force for Lung Health Data Tracker project which will support the public interest by aligning with Pfizer's interest in supporting independent initiatives that advance public policy research and education. The payment will be made direct to the organisation.
	BREAST CANCER NOW	UK			£107,746.67						£40,037,000 (2.69%)	BCN Sponsorship (Service Pledge) To provide part sponsorship to Breast Cancer Now to support their Breast Cancer Now Service Pledge Programme in which Pfizer received various business benefits including 1. A summary of patient and staff feedback 2. Recognition of Pfizer sponsorship 3. Updates from the BCN Patient Experience team regarding service improvement implementation 4. Inclusion in BCN HCP e-newsletter 5. Acknowledgement in PR and communications activities.

Pfizer 2021 Disclosure for Patient Organisations

CAMBRIDGE RARE DISEASE NETWORK	UK			£5,000.00					£163,000 (3%)	Corporate membership of the Cambridge Rare Disease Network (CRDN) in return for various membership rights: <ul style="list-style-type: none"> -Participate in several annual member-only meetings and workshops with presentations, discussion and networking -Company acknowledged in CRDN's annual report -2 passes for CRDN's RAREsummit/fest -Listed as a sponsor on CRDN website and logo displayed -3 place at Companies Forum meetings -Contribute to the group agenda for the Forum meetings -Privileged access to CRDN's future Patient group/Industry partnering Events -Opportunity and acknowledgement of co-authorship of any white papers generated collaboratively through the group.
CARDIOMYOPATHY UK	UK	£21,100.00							£771,829 (2.7%)	To support Cardiomyopathy UK with a charitable donation to support the charity's Regional Advocacy Project which seeks to increase access to appropriate treatments that save and improve the lives of people affected by cardiomyopathy, myocarditis and other conditions that are often Hidden in Heart Failure in the UK.
CHILD GROWTH FOUNDATION	UK					£800.00			£93,300 (0.86%)	To engage with two representatives from the Child Growth Foundation for consultancy services on the Global Growth Hormone Patient/Caregiver support Programme.
CHILD GROWTH FOUNDATION	UK					£900.00			£93,300 (0.96%)	To engage with three representatives from the Child Growth Foundation for consultancy services related to advice on global patient services.
CHILD GROWTH FOUNDATION	UK	£4,200.00							£93,300 (4.5%)	To support Child Growth Foundation with a charitable donation to support a research project to identify patient needs and how much current service delivery/information meets those needs. The project will see a subject matter expert, ideally an endocrine nurse, join the CGF team for one year to conduct the research.
DUCHENNE UK	UK			£1,438.00					£1,637,377 (0.09%)	Entry for 8 x colleague cyclist places for the Duchenne Dash: Around the World.
DUCHENNE UK	UK			£31,376.61					£1,637,377 (1.92%)	Corporate Sponsorship provided to Duchenne UK to support the Patient Organisation Lead Patient Preference project in Duchenne Muscular Dystrophy.
DUCHENNE UK	USA			£80,729.15					£1,637,377 (4.93%)	To fund Duchenne UK with the delivery of Phase 3 of Project Hercules, to develop practical evidence-based tools and a core economic model for use in the appraisal of new treatments for DMD undertaken by health technology assessment agencies with the aim of improving patient access to treatment. Specific areas of research were identified in Phase 1 and 2 of Project Hercules which will be addressed in Phase 3. Sponsorship includes various business benefits to Pfizer.
DUCHENNE UK	USA			£226,376.21					£1,637,377 (13.83%)	To fund Duchenne UK to develop various practical evidence-based tools and a core economic model for use in the appraisal of new treatments for DMD undertaken by health technology assessment agencies in countries outside the UK, including a burden of illness study exploring the economic impact of DMD, with the aim of improving patient access to treatment. Sponsorship includes a benefit to Pfizer of access to data from the burden of illness study.
ECZEMA OUTREACH SUPPORT	USA					£360.69			£390,215 (0.09%)	To engage with a representative from Eczema Outreach Support to participate in a Dermatology Stakeholder Opinion Survey.
ENCEPHALITIS SOCIETY	UK	£10,000.00							£996,911 (1%)	Pfizer funding to Encephalitis Society' support services and events including 'virtual and in person' My Brain My Story, Residential Retreat held in October 2021 as a hybrid virtual and in-person event providing support to people affected by encephalitis.
ENCEPHALITIS SOCIETY	UK	£12,000.00							£996,911 (1.2%)	To support the Encephalitis Society with financial support to deliver a project for World Encephalitis Day with the aim of increasing awareness for and supporting people affected by encephalitis. This will support the public interest by educating individuals and families about sound health practices in order to empower them to improve their health.
FIGHT BLADDER CANCER	Germany					£1,000.00			£303,976 (0.33%)	To engage with a representative of Fight Bladder Cancer on a consultancy basis to participate in a Cancer Strategy Session on the subject of Cancer Control: What should we focus on to make a real difference in Central and Eastern Europe.

Pfizer 2021 Disclosure for Patient Organisations

Patient Organisation (add additional table for each Patient Organisation)	FIGHT BLADDER CANCER	UK	£27,000.00							£303,976 (8.88%)	To support Fight Bladder Cancer with a charitable donation to support Phases 2 and 3 of Fight Bladder Cancer's Exemplar Research & Policy Project to identify the strengths and weakness in current bladder cancer services.
	FUTURE DREAMS	UK	£32,735.00							£406,947.00 (8.04%)	To provide Future Dreams with a grant for the production of one series of the "And then came breast cancer" Podcast.
	GENETIC ALLIANCE UK	UK	£10,000.00							£939,440.00 (1.06%)	To support Genetic Alliance UK with a Charitable donation to support Rare Disease Day 2021. Pfizer's funding is for the intended purpose of the campaign materials and promotion only.
	GENETIC ALLIANCE UK	UK			£12,000.00					£939,440.00 (1.28%)	To support Rare Disease UK which is a campaign run by the Genetic Alliance UK with an Annual Membership of Rare Diseases UK in return for various business benefits including: <ul style="list-style-type: none"> • Invites to exclusive industry events (at least two per year) • Invites to quarterly Stakeholder Meetings with Genetic Alliance UK members (patient organisations) to discuss pre agreed topics • One speaking engagement by Genetic Alliance expert at a chosen event (a roundtable, lunch & learn, discussion panel etc) • Invites to Rare Disease Day parliamentary receptions • Use of Rare Disease Day digital assets, and sight of key messaging and concept ahead of launch • Discounted tickets to Genetic Alliance UK Annual Conference
	GENETIC ALLIANCE UK	USA					£450.00			£939,440.00 (0.048%)	To engage with a representative from the Genetic Alliance UK to provide consultancy services on the Gene Therapy Patient Advisory Council.
	HAEMOPHILIA SOCIETY	UK					£500.00			£814,955 (0.06%)	To engage with representatives of the Haemophilia Society on a consultancy basis to act as advisors in order to gain insights into how to successfully bring gene therapies (GTx) through UK reimbursement frameworks and deliver effective and approvable outcomes-based agreements and supportive patient data tracking systems.
	INTERNATIONAL ALLIANCE PATIENT ORGANISATIONS	USA		£29,017.16						£509,091 (5.7%)	To support the International Alliance of Patient Organisations to deliver the IAPO Virtual African Patient Congress in July 2021 in return for various business benefits.
	INTERNATIONAL BRAIN TUMOUR ALLIANCE	USA			£13,140.28					£8,298,000 (0.16%)	To support the International Brain Tumour Alliance with their Brain Tumour Patient's Charter of Rights and IBTA's Publication projects in return for sponsorship acknowledgement and a half page advertisement in the Brain Tumour magazine in both digital and hard copy.
	INTERNATIONAL GAUCHER ALLIANCE	USA	£25,243.58							Recently registered charity. Financial information not available	Funding provided to support the International Gaucher Alliance to: <ol style="list-style-type: none"> 1. Increase capabilities to support Global Gaucher Community by recruiting and training new volunteers, 2. Support 'Go with Gaucher' initiative to engage young Gaucher patients and identify their challenges, 3. To continue to build the capacities of the IGA membership through information so that they can use this to be more effective in their own countries.
	INTERNATIONAL LONGEVITY CENTRE	USA	£37,375.00							£781,815 (4.78%)	To support International Longevity Centre to undertake a global policy project to understand national approaches to improving pneumococcal update in marginalised groups.
	INTERNATIONAL PATIENT ORGANISATION FOR PRIMARY IMMUNODEFICIENCIES	USA			£43,980.10					£1,033,903 (4.25%)	To sponsor the International Patient Association for Primary Immunosuppressed (IPOPI) New-born screening project for business benefits including: <ul style="list-style-type: none"> • IPOPI Website – company name on corporate partners section • IPOPI Newsletter – company name on corporate partners section • Recognition in IPOPI Annual Report • Mention on official IPOPI Presentations (selected, where appropriate) • Invitations to IPOPI meetings • Opportunity to share official press releases (non-promotional nature) on IPOPI website news section
	INTERNATIONAL PRADER WILLI SYNDROME ASSOCIATION	USA	£69,708.20							£246,585 (28.27%)	A grant provided to the International Prader Willi Syndrome Association to support the IPWSO Project ECHO®. The goal of IPWSO Project ECHO® is to improve the lives of people with Prader-Willi Syndrome (PWS) and their families by connecting, educating and advocating together.

Pfizer 2021 Disclosure for Patient Organisations

KENT MS THERAPY CENTRE	UK	£1,000.00							£517,147 (0.19%)	Funding provided to the Kent MS Therapy Centre to support the running of the counselling service which has become much more in-demand due to Covid-19.
KIDNEY CANCER SUPPORT NETWORK (Now Action Kidney Cancer)	UK	£15,000.00							£102,868 (14.58%)	To support Kidney Cancer Support Network with funding to support a project to create and roll out a national community outreach programme to support Kidney Cancer patients and their carers.
KIDNEY CANCER UK	UK	£7,500.00							£297,702 (2.51%)	Funding provided to Kidney Cancer UK to support the National Kidney Cancer Patient Survey for 2021 and Kidney Cancer Awareness week for 2022.
LEUKAEMIA CARE	USA	£29,080.32							£1,185,076 (2.45%)	Funding provided to Leukaemia Care to support their project entitled "Development of leukaemia information".
MACMILLAN CANCER SUPPORT	UK					£2,000.00			£194,889,000 (0.001%)	Engagement of Macmillan on a consultancy basis to support Pfizer personnel to understand good practice in patient engagement and cocreation when supporting service improvement.
MAGGIE'S	UK	£5,000.00							£21,980,000 (0.23%)	Funding provided to Maggie's to aid the delivery of their support and information services to cancer patients in their centres across the UK.
MARTHA TRUST	UK	£1,500.00							£5,706,418 (0.03%)	Funding provided to the Martha Trust to support with their effort to raise money for 'eye gaze' equipment which will support the public interest by supporting disabled children in the local community.
MENINGITIS NOW	UK	£25,000.00							£2,240,287 (1.11%)	Funding provided to Meningitis Now to support improving the user experience of their Online community project, the funding will go towards external agency costs to maximise the success of the website.
MENINGITIS RESEARCH FOUNDATION	UK	£15,000.00							£3,378,145 (0.44%)	Funding provided to the Meningitis Research Foundation to support their 2021 Awareness Campaigns and Targeted Digital Campaigns to ensure the public remain vigilant to the threat of Meningitis and Septicaemia.
MENINGITIS RESEARCH FOUNDATION	UK		£35,000.00						£3,378,145 (1.04%)	To support the Meningitis Research Foundation with a Corporate Sponsorship for their MRF 2021 Conference in return for a Pfizer symposium.
MENINGITIS RESEARCH FOUNDATION	USA					£2,130.04			£3,378,145 (0.06%)	To engage a member of the Meningitis Research Foundation to speak at a Pfizer Symposium held at the ESPID conference 2021 on the subject of Prioritization of meningococcal vaccination as a preventative strategy and the role of Pfizer's meningococcal portfolio in disease prevention.
MENINGITIS RESEARCH FOUNDATION	USA	£15,000.00							£3,378,145 (0.44%)	To support the Meningitis Research Foundation with a research grant for their project "Global Meningitis Genome Partnership".
MENINGITIS RESEARCH FOUNDATION	USA	£30,000.01							£3,378,145 (0.89%)	Research Grant being providing to the Meningitis Research Foundation to support their project entitled "Meningitis Progress Tracker".
MENINGITIS RESEARCH FOUNDATION	USA	£9,845.87							£3,378,145 (0.29%)	Funding to the Meningitis Research Foundation to support the running of COMO 2021 as a virtual conference. Funding was used to enable: <ul style="list-style-type: none"> •Live translations & subtitles for sessions to boost engagement •Recording of all sessions so that content can be made available afterwards •Member sessions to highlight achievements of the last year and focus on hot topics nominated by members.
MENINGITIS RESEARCH FOUNDATION	USA	£21,088.68							£3,378,145 (0.62%)	Funding provided to the Meningitis Research Foundation to support them to deliver the next phase of the Strengthen Patient Voices project and further build the capacity of civil society organisations to advocate for strengthened policies in support of vaccines, diagnosis and treatment, and support and aftercare for people and families affected. Scaling up the 'Strengthening Patient Voices' programme, taking the learnings from the 3-year pilot programme, to launch and deliver new capacity-building projects with meningitis patient groups around the world so that they can call for better policies for vaccines and care for people and families affected.

Pfizer 2021 Disclosure for Patient Organisations

MENINGITIS RESEARCH FOUNDATION	USA	£29,537.61							£3,378,145 (0.87%)	Funding provided to the Meningitis Research Foundation to support their MRF Reap Programme: Roadmap Engagement and Advocacy Programme in support of WHO Defeat Meningitis 2030 The Roadmap Engagement and Advocacy Programme ("REAP") aims to put civil society at the heart of policy development and awareness-raising nationally and internationally.
MENINGITIS RESEARCH FOUNDATION	USA					£2,505.89			£3,378,145 (0.07%)	To engage a member of the Meningitis Research Foundation to speak at a Pfizer meeting to deliver a presentation describing the WHO Detecting Meningitis Roadmap, highlighting the expectations for individual countries to reduce meningitis cases and indicating how Pfizer medical colleagues can facilitate this.
NATIONAL VOICES	UK	£15,200.00							£774,819 (1.96%)	Funding provided to National Voices for their activities in relation to work with their 180 charity members to host a series of member led roundtables on different racism themes that are of relevance to national Voices wide coalition of health and social care charities.
PRETTY 'N PINK	UK	£500.00							£173,200 (0.29%)	To provide Pretty 'N Pink with a charitable donation of £500 from Employee fund raising from a team of 30 Pfizer UK Oncology Business Unit Employees completing their Extreme UK Settlements Challenge.
REALISE ADVOCACY LTD	UK			£10,000.00					Recently incorporated. Financial information not available	To support Realise Advocacy Ltd to deliver Navigating Health Technology Assessments (HTA) Webinar in return for: Pfizer Logo on the report, poster and webinar presentation. The opportunity to include a quote in the report and in publicity materials for the pilot.
ROYAL NATIONAL INSTITUTE OF BLIND PEOPLE	UK					£3,725.64			£86,486,000 (0.004%)	Fee for service for the development of Braille signage for Pfizer Walton Oaks offices.
THE PATIENTS ASSOCIATION	UK			£15,000.00					£471,631 (3.18%)	To support The Patients Association with a Corporate Membership in return for: Regular updates on The Patients Association work through reports • Invitations to The Patients Association briefings/meetings • Opportunities for senior charity staff to attend Pfizer meetings/staff briefings • Opportunities for joint research projects and the use of The Patients Association logo on approved publications • Joint media opportunities • Opportunities to include articles in The Patients Association weekly news publication • Access to The Patients Association network of patients/ambassadors for specific consultations • Acknowledgement in The Patients Association's annual report • Pfizer logo on The Patients Association's website at www.patients-association.org.uk/our-supporters .
THE PITUITARY FOUNDATION	UK	£10,520.00							£528,307 (1.99%)	To support The Pituitary Foundation with a charitable donation to support their Patient and Family Services to continue to provide front line support to patients who need it, specifically those who are classed as high risk with regard to COVID-19.
THROMBOSIS UK	UK					£550.00			£205,791 (0.26%)	To engage with a representative of Thrombosis UK to deliver consultancy services on Sharing perspectives on patient experiences.
THROMBOSIS UK	UK		£1,950.00						£205,791 (0.95%)	To support Thrombosis UK to deliver "NTW21 Virtual Conference" on 3rd to 9th May 2021 in return for: <ul style="list-style-type: none"> - Virtual exhibition space on the NTW21 secure platform, - Organisation branding, logo, and banner - 300-word summary - Four website/social media links - Up to eight film/interactive assets suitable for an HCP audience - Option to include email link to 'request information/request a meeting' - Sponsored Symposium held during the live conference sessions (3rd - 7th) - Option to retain access for registered HCPs to view recording of Sponsored Symposium throughout May on the NTW21 platform - Complimentary access to attend webinars

Pfizer 2021 Disclosure for Patient Organisations

Organisation	Country	Value	Value	Value	Value	Value	Value	Value	Value	Value	Description
THROMBOSIS UK	UK	£1,950.00								£205,791 (0.95%)	To support Thrombosis UK to deliver a virtual conference on "Let's Talk about Clots" on the 11th - 15th October 2021 in return for: <ul style="list-style-type: none"> Each sponsor is offered a dedicated exhibition area within the secure platform which includes: <ul style="list-style-type: none"> Organisation branding, logo, and banner 300-word summary Website/social media links Up to eight film/interactive assets suitable for an HCP audience Option to include 'request information/leave a question' <ul style="list-style-type: none"> Complimentary access to attend webinars Let's Talk Clots VC banner for Twitter and social media Area open to HCP attendees 24/7 between 10th October – 12th November 2021
UK ATTR AMYLOIDOSIS PATIENTS	UK	£5,000.00								£31,258 (15.99%)	To support UK Amyloidosis Patient Association (UKATPA) with a Business Donation to support the development of a website on the topic of ATTR Amyloidosis to raise patient, caregivers and the health care community awareness of this rare disease.
VERSUS ARTHRITIS	UK					£486.00				£25,438,000 (0.0019%)	To engage a member of Versus Arthritis as a consultant to development of and participation in a Pfizer Advisory Board.
VERSUS ARTHRITIS	UK	£95,000.00								25,438,000 (0.37%)	Funding provided to Versus Arthritis to publish a summary report with data on the unmet needs of people living with Osteoarthritis with recommendations to improve NHS care. The report will provide new evidence and insight from patients on Osteoarthritis since 2012 Payment will be made directly to Versus Arthritis.

Non-Promotional Certificate UK

Name Disclosure for Patient Organisations

Document Number PP-UNP-GBR-1272

NON-PROMOTIONAL ITEM CERTIFIED FOR USE

The below signatories have examined the electronic final form of this material and in their belief it complies with the Code.

Medical Director	Name: Samantha Howland Signature Date: 28-Jun-2022 14:16:17 GMT+0000 Reason: Non-Promotional item certified for use
------------------	---